oncotomskСибирский онкологический журналSiberian journal of oncology1814-48612312-3168Tomsk National Research Medical Сепtеr of the Russian Academy of Sciences10.21294/1814-4861-2019-18-4-78-84oncotomsk-1144Research ArticleОБЗОРЫREVIEWSСОВРЕМЕННЫЕ АСПЕКТЫ ЛЕЧЕНИЯ РАКА ПИЩЕВОДАMODERN ASPECTS OF TREATMENT OF ESOPHAGEAL CANCERhttps://orcid.org/0000-0003-2804-4227УрмоновУ. Б.UrmonovU. B.

аспирант отделения абдоминальной онкологии, 

г. Томск, 634009, пер. Кооперативный, 5

MD, Postgraduate, Department of abdominal oncology,

5, Kooperativny Street, 634009-Tomsk

UrmonovUB@oncology.tomsk.ruhttps://orcid.org/0000-0002-2748-0644ДобродеевА. Ю.DobrodeevA. Yu.

доктор медицинских наук, ведущий научный сотрудник отделения абдоминальной онкологии, 

г. Томск, 634009, пер. Кооперативный, 5

MD, DSc, Leading Researcher, Department of abdominal oncology,

5, Kooperativny Street, 634009-Tomsk

https://orcid.org/0000-0002-4701-0375АфанасьевС. Г.AfanasyevS. G.

доктор медицинских наук, профессор, заведующий отделением абдоминальной онкологии, 

г. Томск, 634009, пер. Кооперативный, 5

MD, DSc, Professor, Head of the Department of Abdominal Oncology,

5, Kooperativny Street, 634009-Tomsk

АвгустиновичА. В.AvgustinovichA. V.

кандидат медицинских наук, научный сотрудник отделения абдоминальной онкологии,

г. Томск, 634009, пер. Кооперативный, 5

MD, PhD, Researcher, Department of abdominal oncology,

5, Kooperativny Street, 634009-Tomsk

https://orcid.org/0000-0001-7234-4708ЧеремисинаО. В.CheremisinaO. V.

доктор медицинских наук, заведующая эндоскопическим отделением, 

г. Томск, 634009, пер. Кооперативный, 5

MD, DSc, Head of the Department of Endoscopy,

5, Kooperativny Street, 634009-Tomsk

CheremisinaOV@oncology.tomsk.ruНаучно-исследовательский институт онкологии, Томский национальный исследовательский медицинский центр Российской академии наукРоссияCancer Research Institute, Tomsk National Research Medical Center, Russian Academy of SciencesRussian Federation2019010920191847884Copyright © Урмонов У.Б., Добродеев А.Ю., Афанасьев С.Г., Августинович А.В., Черемисина О.В., 20192019Урмонов У.Б., Добродеев А.Ю., Афанасьев С.Г., Августинович А.В., Черемисина О.В.Urmonov U.B., Dobrodeev A.Y., Afanasyev S.G., Avgustinovich A.V., Cheremisina O.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.siboncoj.ru/jour/article/view/1144

Цель исследования – представить современные данные о различных методах лечения раннего и местнораспространенного рака пищевода.

Материал и методы

Материал и методы. Проведен поиск доступных литературных источников, опубликованных в базах Pubmed, Medline, Elibrary, Cochrane Library, CyberLeninka, Global Health и др. Было найдено и проанализировано 123 источника, опубликованных с 2001 по 2018 гг.

Результаты

Результаты. Рак пищевода занимает седьмое место среди наиболее распространенных злокачественных новообразований в мире. Прогноз при раке пищевода считается благоприятным только на самых ранних стадиях заболевания. Применение эндоскопических технологий обеспечивает минимально инвазивный подход к лечению рака слизистой оболочки пищевода и значительно увеличивает выживаемость больных. Хирургическое лечение остается основным методом воздействия, однако при местнораспространенном раке пищевода требуется мультимодальный подход, включающий рациональное сочетание радикальной операции с химио- и/или лучевой терапией. Во многих странах предоперационная химиотерапия вошла в стандарт лечения при раке пищевода II–III стадии. Вместе с тем разработка и внедрение новых методов лечения рака пищевода до сих пор остается актуальной проблемой современной онкологии. На поздних стадиях заболевания основным методом лечения является паллиативная химио- или химиолучевая терапия.

Заключение

Заключение. До сих пор во всем мире выбор метода лечения рака пищевода остается актуальной проблемой и зависит от вида опухоли, стадии заболевания, функционального статуса пациента. 

The purpose of the study was to provide current data about various methods of treatment of early and locally advanced esophageal cancer.

Material and Methods

Material and Methods. A search was made on available literature sources published in the Pubmed, Medline, Elibrary, Cochrane Library, CyberLeninka, Global Health and other databases. 123 articles published from 2001 to 2018 were found and analyzed to write this review.

Results

Results. Esophageal cancer is the 7-th most common cancer worldwide. Esophageal cancer has a favorable prognosis only in patients with early stage cancer. The use of endoscopic technology provides a minimally invasive approach to the treatment of esophageal cancer and significantly increases survival of patients. Surgical resection remains the mainstay of treatment for esophageal cancer. For patients with locally advanced esophageal cancer, a multimodal approach is required, including a rational combination of radical surgery with chemo and/or radiation therapy. In many countries, preoperative chemotherapy has entered the standard of treatment for II–III stages of esophagus cancer. However, the development of novel approaches to the treatment of esophageal cancer is of great importance. For advanced cancer patients, palliative chemo- or chemoradiotherapy remains the main treatment modality.

Conclusion

Conclusion. The choice of the treatment option for esophageal cancer remains a challenging clinical problem and depends on the particular type of cancer, tumor stage, functional status of patients. 

рак пищеводахирургическое лечениехимиотерапияхимиолучевая терапиявыживаемостьesophagus cancersurgical treatmentchemotherapychemoradiotherapysurvivalReferencesTorre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar; 65(2): 87–108. doi: 10.3322/caac.21262.Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015 Mar; 65(2): 87–108. doi: 10.3322/caac.21262.Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov; 68(6): 394–424. doi: 10.3322/caac.21492.Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov; 68(6): 394–424. doi: 10.3322/caac.21492.Arnold M., Soerjomataram I., Ferlay J., Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015 Mar; 64(3): 381–7. doi: 10.1136/gutjnl-2014-308124.Arnold M., Soerjomataram I., Ferlay J., Forman D. Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2015 Mar; 64(3): 381–7. doi: 10.1136/gutjnl-2014-308124.Деньгина Н.В. Современные терапевтические возможности при раке пищевода. Практическая онкология. 2012; 13(4): 276–288.Dengina N.V. Modern therapeutic opportunities for cancer of the esophagus. Practical oncology. 2012; 13 (4): 276–288. (in Russian).Писарева Л.Ф., Одинцова И.Н., Ананина О.А., Афанасьев С.Г., Волков М.Ю., Ляхова Н.П. Заболеваемость раком пищевода в Томской области. Сибирский онкологический журнал. 2014; 1: 33–36.Pisareva L.F., Odintsova I.N., Ananina O.A., Afanasyev S.G., Volkov M.Yu., Lyakhova N.P. Esophageal cancer incidence in Tomsk region. Siberian Journal of Oncology. 2014. 1; 33–36. (in Russian).Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2017 году. М., 2018. 66–69.Kaprin A.D., Starinsky V.V., Petrova G.V. The state of cancer care to the population of Russia in 2017. Moscow, 2018. 66–69. (in Russian).Klevebro F., Lindblad M., Johansson J., Lundell L., Nilsson M. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastrooesophageal junction based on a national data registry. Br J Surg. 2016 Dec; 103(13): 1864–1873. doi: 10.1002/bjs.10304.Klevebro F., Lindblad M., Johansson J., Lundell L., Nilsson M. Outcome of neoadjuvant therapies for cancer of the oesophagus or gastrooesophageal junction based on a national data registry. Br J Surg. 2016 Dec; 103(13): 1864–1873. doi: 10.1002/bjs.10304.Napier K.J., Scheerer M., Misra S. Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014 May 15; 6(5): 112–20. doi: 10.4251/wjgo.v6.i5.112.Napier K.J., Scheerer M., Misra S. Esophageal cancer: a review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol. 2014 May 15; 6(5): 112–20. doi: 10.4251/wjgo.v6.i5.112.Watson A. Operable esophageal cancer: current results from the West. World J Surg. 1994 May-Jun; 18(3): 361–6.Watson A. Operable esophageal cancer: current results from the West. World J Surg. 1994 May-Jun; 18(3): 361–6.Zhang D.W., Cheng G.Y., Huang G.J., Zhang R.G., Liu X.Y., Mao Y.S., Wang Y.G., Chen S.J., Zhang L.Z., Wang L.J., De Zhang C., Yang L., Meng P.J. Operable squamous esophageal cancer: current results from the East. World Journal of Surgery. 1994 May-Jun; 18(3): 347–354.Zhang D.W., Cheng G.Y., Huang G.J., Zhang R.G., Liu X.Y., Mao Y.S., Wang Y.G., Chen S.J., Zhang L.Z., Wang L.J., De Zhang C., Yang L., Meng P.J. Operable squamous esophageal cancer: current results from the East. World Journal of Surgery. 1994 May-Jun; 18(3): 347–354.Kelsen D.P., Winter K.A., Gunderson L.L., Mortimer J., Estes N.C., Haller D.G., Ajani J.A., Kocha W., Minsky B.D., Roth J.A., Willett C.G.; Radiation Therapy Oncology Group; USA Intergroup. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007 Aug 20; 25(24): 3719–25. doi: 10.1200/JCO.2006.10.4760.Kelsen D.P., Winter K.A., Gunderson L.L., Mortimer J., Estes N.C., Haller D.G., Ajani J.A., Kocha W., Minsky B.D., Roth J.A., Willett C.G.; Radiation Therapy Oncology Group; USA Intergroup. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007 Aug 20; 25(24): 3719–25. doi: 10.1200/JCO.2006.10.4760.Wang K.K., Prasad G., Tian J. Endoscopic mucosal resection and endoscopic submucosal dissection in esophageal and gastric cancers. Curr Opin Gastroenterol. 2010 Sep; 26(5): 453–8. doi: 10.1097/MOG.0b013e32833e4712.Wang K.K., Prasad G., Tian J. Endoscopic mucosal resection and endoscopic submucosal dissection in esophageal and gastric cancers. Curr Opin Gastroenterol. 2010 Sep; 26(5): 453–8. doi: 10.1097/MOG.0b013e32833e4712.Shah A.K., Wolfsen H.C., Hemminger L.L., Shah A.A., DeVault K.R. Changes in esophageal motility after porfimer sodium photodynamic therapy for Barrett’s dysplasia and mucosal carcinoma. Diseases of Esophagus. 2006; 19(5): 335–9. doi: 10.1111/j.1442-2050.2006.00592.x.Shah A.K., Wolfsen H.C., Hemminger L.L., Shah A.A., DeVault K.R. Changes in esophageal motility after porfimer sodium photodynamic therapy for Barrett’s dysplasia and mucosal carcinoma. Diseases of Esophagus. 2006; 19(5): 335–9. doi: 10.1111/j.1442-2050.2006.00592.x.Pech O., Behrens A., May A.,Nachbar L., Gossner L., Rabenstein T., Manner H., Guenter E., Huijsmans J., Vieth M., Stolte M., Ell C. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008 Sep; 57(9): 1200–6. doi: 10.1136/gut.2007.142539.Pech O., Behrens A., May A.,Nachbar L., Gossner L., Rabenstein T., Manner H., Guenter E., Huijsmans J., Vieth M., Stolte M., Ell C. Long-term results and risk factor analysis for recurrence after curative endoscopic therapy in 349 patients with high-grade intraepithelial neoplasia and mucosal adenocarcinoma in Barrett’s oesophagus. Gut. 2008 Sep; 57(9): 1200–6. doi: 10.1136/gut.2007.142539.Prasad G.A., Wu T.T., Wigle D.A., Buttar N.S., Wongkeesong L.M., Dunagan K.T., Lutzke L.S., Borkenhagen L.S., Wang K.K. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology. 2009; 137(3): 815–23. doi: 10.1053/j.gastro.2009.05.059.Prasad G.A., Wu T.T., Wigle D.A., Buttar N.S., Wongkeesong L.M., Dunagan K.T., Lutzke L.S., Borkenhagen L.S., Wang K.K. Endoscopic and surgical treatment of mucosal (T1a) esophageal adenocarcinoma in Barrett’s esophagus. Gastroenterology. 2009; 137(3): 815–23. doi: 10.1053/j.gastro.2009.05.059.Ozawa S. The registration committee for esophageal cancer, the Japan esophageal society. II. Clinical results of patients treated with endoscopy in 2004. Comprehensive registry of esophageal cancer in Japan, 2004. Chiba: The Japan Esophageal Society, 2012. 14–20.Ozawa S. The registration committee for esophageal cancer, the Japan esophageal society. II. Clinical results of patients treated with endoscopy in 2004. Comprehensive registry of esophageal cancer in Japan, 2004. Chiba: The Japan Esophageal Society, 2012. 14–20.Takahashi H., Arimura Y., Masao H., Okahara S., Tanuma T., Kodaira J., Kagaya H., Shimizu Y., Hokari K., Tsukagoshi H., Shinomura Y., Fujita M. Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc. 2010 Aug; 72(2): 255–64, 264.e1-2. doi: 10.1016/j.gie.2010.02.040.Takahashi H., Arimura Y., Masao H., Okahara S., Tanuma T., Kodaira J., Kagaya H., Shimizu Y., Hokari K., Tsukagoshi H., Shinomura Y., Fujita M. Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc. 2010 Aug; 72(2): 255–64, 264.e1-2. doi: 10.1016/j.gie.2010.02.040.Nakagawa K., Koike T., Iijima K., Shinkai H., Hatta W., Endo H., Ara N., Uno K., Asano N., Imatani A., Shimosegawa T. Comparison of the longterm outcomes of endoscopic resection for superficial squamous cell carcinoma and adenocarcinoma of the esophagus in Japan. Am J Gastroenterol. 2014 Mar; 109(3): 348–56. doi: 10.1038/ajg.2013.450.Nakagawa K., Koike T., Iijima K., Shinkai H., Hatta W., Endo H., Ara N., Uno K., Asano N., Imatani A., Shimosegawa T. Comparison of the longterm outcomes of endoscopic resection for superficial squamous cell carcinoma and adenocarcinoma of the esophagus in Japan. Am J Gastroenterol. 2014 Mar; 109(3): 348–56. doi: 10.1038/ajg.2013.450.Crumley A.B., Going J.J., McEwan K., McKernan M., Abela J.E., Shearer C.J., Stanley A.J., Stuart R.C. Endoscopic mucosal resection for gastroesophageal cancer in a U. K. population. Longterm follow-up of a consecutive series. Surg Endosc. 2011 Feb; 25(2): 543–8. doi: 10.1007/s00464-010-1213-9.Crumley A.B., Going J.J., McEwan K., McKernan M., Abela J.E., Shearer C.J., Stanley A.J., Stuart R.C. Endoscopic mucosal resection for gastroesophageal cancer in a U. K. population. Longterm follow-up of a consecutive series. Surg Endosc. 2011 Feb; 25(2): 543–8. doi: 10.1007/s00464-010-1213-9.Park Y.M., Cho E., Kang H.Y., Kim J.M. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc. 2011 Aug; 25(8): 2666–77. doi: 10.1007/ s00464-011-1627-z.Park Y.M., Cho E., Kang H.Y., Kim J.M. The effectiveness and safety of endoscopic submucosal dissection compared with endoscopic mucosal resection for early gastric cancer: a systematic review and metaanalysis. Surg Endosc. 2011 Aug; 25(8): 2666–77. doi: 10.1007/ s00464-011-1627-z.Ishihara R.,Iishi H., Uedo N., Takeuchi Y., Yamamoto S., Yamada T., Masuda E., Higashino K., Kato M., Narahara H., Tatsuta M. Comparison of EMR and endoscopic submucosal dissection for en bloc resection of early esophageal cancers in Japan. Gastrointest Endosc. 2008 Dec; 68(6): 1066–72. doi: 10.1016/j.gie.2008.03.1114.Ishihara R.,Iishi H., Uedo N., Takeuchi Y., Yamamoto S., Yamada T., Masuda E., Higashino K., Kato M., Narahara H., Tatsuta M. Comparison of EMR and endoscopic submucosal dissection for en bloc resection of early esophageal cancers in Japan. Gastrointest Endosc. 2008 Dec; 68(6): 1066–72. doi: 10.1016/j.gie.2008.03.1114.Давыдов М.И., Стилиди И.С., Бохян В.Ю., Сулейманов Э.А., Трякин А.А., Кононец П.В., Тюляндин С.А. Промежуточные результаты применения предоперационной химиотерапии и расширенной субтотальной резекции пищевода при раке. Анналы хирургии. 2005; 3: 27–32.Davydov M.I., Stilidi I.S., Bokhyan V.YU., Suleymanov Ye.A., Tryakin A.A., Kononets P.V., Tyulyandin S.A. Intermediate results of the use of preoperative chemotherapy and extended subtotal esophageal resection for cancer. Annals of surgery. 2005; 3: 27–32. (in Russian).Hiroyuki K., Yasumasa N., Tsuneo O., Hiroyuki K. Guidelines for diagnosis and treatment of carcinoma of the esophagus april 2012 edited by the Japan Esophageal Society. Esophagus. 2015; 12(1): 1–30.Hiroyuki K., Yasumasa N., Tsuneo O., Hiroyuki K. Guidelines for diagnosis and treatment of carcinoma of the esophagus april 2012 edited by the Japan Esophageal Society. Esophagus. 2015; 12(1): 1–30.Kato H., Nakajima M. Treatments for esophageal cancer: a review. Gen Thorac Cardiovasc Surg. 2013 Jun; 61(6): 330–5. doi: 10.1007/ s11748-013-0246-0.Kato H., Nakajima M. Treatments for esophageal cancer: a review. Gen Thorac Cardiovasc Surg. 2013 Jun; 61(6): 330–5. doi: 10.1007/ s11748-013-0246-0.Hulscher J.B., van Sandick J.W., de Boer A.G., Wijnhoven B.P., Tijssen J.G., Fockens P., Stalmeier P.F., ten Kate F.J., van Dekken H., Obertop H., Tilanus H.W., van Lanschot J.J. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002 Nov; 347(21): 1662–9.Hulscher J.B., van Sandick J.W., de Boer A.G., Wijnhoven B.P., Tijssen J.G., Fockens P., Stalmeier P.F., ten Kate F.J., van Dekken H., Obertop H., Tilanus H.W., van Lanschot J.J. Extended transthoracic resection compared with limited transhiatal resection for adenocarcinoma of the esophagus. N Engl J Med. 2002 Nov; 347(21): 1662–9.Тюляндин С.А., Носов Д.А., Переводчикова Н.И. Минимальные клинические рекомендации Европейского Общества медицинской онкологии (ESMO). М., 2010. 436.Tyulyandin S.A., Nosov D.A., Perevodchikova N.I. Minimum clinical guidelines of the European Society of Medical Oncology (ESMO). Moscow, 2010. 436. (in Russian).Соколов В.В., Павлов П.В., Чиссов В.И., Вашакмадзе Л.А., Бойко А.В. Методы реканализации и стентирования при стенозирующем раке пищевода, желудка и двенадцатиперстной кишки. Сибирский онкологический журнал. 2012; 5: 64–73.Sokolov V.V., Pavlov P.V., Chissov V.I., Vashakmadze L.A., Boyko A.V. Methods of recanalization and stenting for stenotic cancer of the esophagus, stomach and duodenum. Siberian Journal of Oncology. 2012; 5: 64–73. (in Russian).NCCN Clinical Practice Guidelines in Oncology. Esophageal and Esophagogastric Junction Cancers. Version 1.2015 [Internet]. URL: www. NCCN.org. (cited 1.03.2019).NCCN Clinical Practice Guidelines in Oncology. Esophageal and Esophagogastric Junction Cancers. Version 1.2015 [Internet]. URL: www. NCCN.org. (cited 1.03.2019).Peyre C.G., Hagen J.A., DeMeester S.R., Altorki N.K., Ancona E., Griffin S.M., Hölscher A., Lerut T., Law S., Rice T.W., Ruol A., van Lanschot J.J., Wong J., DeMeester T.R. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008 Oct; 248(4): 549–556. doi: 10.1097/SLA.0b013e318188c474.Peyre C.G., Hagen J.A., DeMeester S.R., Altorki N.K., Ancona E., Griffin S.M., Hölscher A., Lerut T., Law S., Rice T.W., Ruol A., van Lanschot J.J., Wong J., DeMeester T.R. The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008 Oct; 248(4): 549–556. doi: 10.1097/SLA.0b013e318188c474.Rizk N.P.,Ishwaran H.,Rice T.W.,Chen L.Q.,Schipper P.H.,Kesler K.A., Law S., Lerut T.E., Reed C.E., Salo J.A., Scott W.J., Hofstetter W.L., Watson T.J., Allen M.S., Rusch V.W., Blackstone E.H. Optimum lymphadenectomy for esophageal cancer. Ann. Surg. 2010 Jan; 251(1): 46–50. doi: 10.1097/SLA.0b013e3181b2f6ee.Rizk N.P.,Ishwaran H.,Rice T.W.,Chen L.Q.,Schipper P.H.,Kesler K.A., Law S., Lerut T.E., Reed C.E., Salo J.A., Scott W.J., Hofstetter W.L., Watson T.J., Allen M.S., Rusch V.W., Blackstone E.H. Optimum lymphadenectomy for esophageal cancer. Ann. Surg. 2010 Jan; 251(1): 46–50. doi: 10.1097/SLA.0b013e3181b2f6ee.Klevebro F., Ekman S., Nilsson M. Current trends in multimodality treatment of esophageal and gastroesophageal junction cancer – Review article. Surg Oncol. 2017 Sep; 26(3): 290–295. doi: 10.1016/j. suronc.2017.06.002.Klevebro F., Ekman S., Nilsson M. Current trends in multimodality treatment of esophageal and gastroesophageal junction cancer – Review article. Surg Oncol. 2017 Sep; 26(3): 290–295. doi: 10.1016/j. suronc.2017.06.002.Miyata H., Yamasaki M., Takahashi T., Kurokawa Y., Nakajima K., Takiguchi S., Mori M., Doki Y. Larynx-preserving limited resection and free jejunal graft for carcinoma of the cervical esophagus. World J Surg. 2013 Mar; 37(3): 551–7. doi: 10.1007/s00268-012-1875-7.Miyata H., Yamasaki M., Takahashi T., Kurokawa Y., Nakajima K., Takiguchi S., Mori M., Doki Y. Larynx-preserving limited resection and free jejunal graft for carcinoma of the cervical esophagus. World J Surg. 2013 Mar; 37(3): 551–7. doi: 10.1007/s00268-012-1875-7.Lee H.S., Park S.Y., Jang H.J., Kim M.S., Lee J.M., Zo J.I. Free jejunal graft for esophageal reconstruction using end-to-side vascular anastomosis and extended pharyngo-jejunostomy. Ann Thorac Surg. 2012 Jun; 93(6): 1850–4. doi: 10.1016/j.athoracsur.2012.01.068.Lee H.S., Park S.Y., Jang H.J., Kim M.S., Lee J.M., Zo J.I. Free jejunal graft for esophageal reconstruction using end-to-side vascular anastomosis and extended pharyngo-jejunostomy. Ann Thorac Surg. 2012 Jun; 93(6): 1850–4. doi: 10.1016/j.athoracsur.2012.01.068.Афанасьев С.Г., Добродеев А.Ю, Урмонов У.Б., Черемисина О.В. Эффективность неоадъювантной химиотерапии при комбинированном лечении больных раком пищевода. Поволжский онкологический вестник. 2018; 9(5): 44–50.Afanasyev S.G., Dobrodeyev A.Yu., Urmonov U.B., Cheremisina O.V. Efficiency of neoadiuvant chemotherapy in combined treatment of patients with esophagus cancer. Oncology bulletin of the Volga region. 2018; 9(5): 44–50. (in Russian).Triboulet J.P., Mariette C., Chevalier D., Amrouni H. Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases. Arch Surg. 2001; 136: 1164–70.Triboulet J.P., Mariette C., Chevalier D., Amrouni H. Surgical management of carcinoma of the hypopharynx and cervical esophagus: analysis of 209 cases. Arch Surg. 2001; 136: 1164–70.Левченко Е.В., Канаев С.В., Тюряева Е.И., Дворецкий С.Ю., Щербаков А.М., Комаров И.В., Хандогин Н.В., Иванцов А.О., Шабатуров Л.Ю. Результаты комплексного лечения больных раком грудного отдела пищевода. Вопросы онкологии. 2016; 62(2): 302–309.Levchenko E.V., Kanaev S.V., Tyuryaeva E.I., Dvoretsky S.Yu., Shcherbakov A.M., Komarov I.V., Khandogin N.V., Ivantsov A.O., Shabaturov L.Yu. Results of complex treatment of patients with thoracic esophageal cancer. Questions oncology. 2016; 62(2): 302–309. (in Russian)..Добродеев А.Ю., Афанасьев С.Г., Тузиков С.А., Урмонов У.Б. Комбинированное лечение рака пищевода с использованием предоперационной химиотерапии. Материалы IV Петербургского международного онкологического форума «Белые ночи 2018». СПб., 2018: 15.Dobrodeev A.Yu., Afanasyev S.G., Tuzikov S.A., Urmonov U.B. Combined treatment of esophageal cancer using preoperative chemotherapy. Materials of the IV St. Petersburg International Oncological Forum «Belyye nochi 2018». St. Petersburg, 2018: 15. (in Russian).Kato H., Miyazaki T.,Nakajima M., Takita J.,Kimura H., Faried A., Sohda M.,Fukai Y.,Masuda N.,Fukuchi M.,Manda R.,Ojima H.,Tsukada K., Kuwano H., Oriuchi N., Endo K. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 2005 Jan; 103(1): 148–56. doi: 10.1002/cncr.20724.Kato H., Miyazaki T.,Nakajima M., Takita J.,Kimura H., Faried A., Sohda M.,Fukai Y.,Masuda N.,Fukuchi M.,Manda R.,Ojima H.,Tsukada K., Kuwano H., Oriuchi N., Endo K. The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma. Cancer. 2005 Jan; 103(1): 148–56. doi: 10.1002/cncr.20724.Allum W.H., Stenning S.P., Bancewicz J., Clark P.I., Langley R.E. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009 Oct; 27(30): 5062–7. doi: 10.1200/JCO.2009.22.2083.Allum W.H., Stenning S.P., Bancewicz J., Clark P.I., Langley R.E. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009 Oct; 27(30): 5062–7. doi: 10.1200/JCO.2009.22.2083.Ando N., Kato H., Igaki H., Shinoda M., Ozawa S., Shimizu H., Nakamura T., Yabusaki H., Aoyama N., Kurita A., Ikeda K., Kanda T., Tsujinaka T., Nakamura K., Fukuda H. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012 Jan; 19(1): 68–74. doi: 10.1245/s10434-011-2049-9.Ando N., Kato H., Igaki H., Shinoda M., Ozawa S., Shimizu H., Nakamura T., Yabusaki H., Aoyama N., Kurita A., Ikeda K., Kanda T., Tsujinaka T., Nakamura K., Fukuda H. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012 Jan; 19(1): 68–74. doi: 10.1245/s10434-011-2049-9.Sjoquist K.M., Burmeister B.H., Smithers B.M., Zalcberg J.R., Simes R.J., Barbour A., Gebski V.;Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011 Jul; 12(7): 681–92. doi: 10.1016/S1470-2045(11)70142-5.Sjoquist K.M., Burmeister B.H., Smithers B.M., Zalcberg J.R., Simes R.J., Barbour A., Gebski V.;Australasian Gastro-Intestinal Trials Group. Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011 Jul; 12(7): 681–92. doi: 10.1016/S1470-2045(11)70142-5.Baba Y., Watanabe M., Yoshida N., Baba H. Neoadjuvant treatment for esophageal squamous cell carcinoma. World J Gastrointest Oncol. 2014 May 15; 6(5): 121–8. doi: 10.4251/wjgo.v6.i5.121.Baba Y., Watanabe M., Yoshida N., Baba H. Neoadjuvant treatment for esophageal squamous cell carcinoma. World J Gastrointest Oncol. 2014 May 15; 6(5): 121–8. doi: 10.4251/wjgo.v6.i5.121.Zhang Y.S., Gao B.R., Wang H.J., Su Y.F., Yang Y.Z., Zhang J.H., Wang C. Comparison of anastomotic leakage and stricture formation following layered and stapler oesophagogastric anastomosis for cancer: a prospective randomized controlled trial. J Int Med Res. 2010 Jan; 38(1): 227–33. doi: 10.1177/147323001003800127.Zhang Y.S., Gao B.R., Wang H.J., Su Y.F., Yang Y.Z., Zhang J.H., Wang C. Comparison of anastomotic leakage and stricture formation following layered and stapler oesophagogastric anastomosis for cancer: a prospective randomized controlled trial. J Int Med Res. 2010 Jan; 38(1): 227–33. doi: 10.1177/147323001003800127.Ando N., Iizuka T., Ide H., Ishida K., Shinoda M., Nishimaki T., Takiyama W., Watanabe H., Isono K.,Aoyama N., Makuuchi H., Tanaka O., Yamana H.,Ikeuchi S.,Kabuto T.,Nagai K., Shimada Y.,Kinjo Y.,Fukuda H., Japan Clinical Oncology Group. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study – JCOG9204. J Clin Oncol. 2003 Dec; 21(24): 4592–6. doi: 10.1200/JCO.2003.12.095.Ando N., Iizuka T., Ide H., Ishida K., Shinoda M., Nishimaki T., Takiyama W., Watanabe H., Isono K.,Aoyama N., Makuuchi H., Tanaka O., Yamana H.,Ikeuchi S.,Kabuto T.,Nagai K., Shimada Y.,Kinjo Y.,Fukuda H., Japan Clinical Oncology Group. Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study – JCOG9204. J Clin Oncol. 2003 Dec; 21(24): 4592–6. doi: 10.1200/JCO.2003.12.095.Yoshida N.,Baba Y.,Shigaki H.,Harada K.,Iwatsuki M.,Sakamoto Y., Miyamoto Y.,Kurashige J.,Kosumi K., Tokunaga R., Watanabe M., Baba H. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvantchemotherapy for resectable advanced esophageal squamous cell carcinoma. Int J Clin Oncol. 2016 Dec; 21(6): 1071–1078. doi: 10.1007/s10147-016-0994-9.Yoshida N.,Baba Y.,Shigaki H.,Harada K.,Iwatsuki M.,Sakamoto Y., Miyamoto Y.,Kurashige J.,Kosumi K., Tokunaga R., Watanabe M., Baba H. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvantchemotherapy for resectable advanced esophageal squamous cell carcinoma. Int J Clin Oncol. 2016 Dec; 21(6): 1071–1078. doi: 10.1007/s10147-016-0994-9.Rackley T., Leong T., Foo M., Crosby T. Definitive chemoradiotherapy for oesophageal cancer – a promising start on an exciting journey. Clin Oncol (R Coll Radiol). 2014 Sep; 26(9): 533–40. doi: 10.1016/j. clon.2014.06.001.Rackley T., Leong T., Foo M., Crosby T. Definitive chemoradiotherapy for oesophageal cancer – a promising start on an exciting journey. Clin Oncol (R Coll Radiol). 2014 Sep; 26(9): 533–40. doi: 10.1016/j. clon.2014.06.001.Cooper S.L., Russo J.K., Chin S. Definitive chemoradiotherapy for esophageal carcinoma. Surg Clin North Am. 2012 Oct; 92(5): 1213–48. doi: 10.1016/j.suc.2012.07.013.Cooper S.L., Russo J.K., Chin S. Definitive chemoradiotherapy for esophageal carcinoma. Surg Clin North Am. 2012 Oct; 92(5): 1213–48. doi: 10.1016/j.suc.2012.07.013.Conroy T.,Galais M.P.,Raoul J.L.,Bouché O.,Gourgou-Bourgade S., Douillard J.Y., Etienne P.L., Boige V., Martel-Lafay I., Michel P., LlacerMoscardo C., François E. , Créhange G., Abdelghani M.B., Juzyna B., Bedenne L., Adenis A.; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014 Mar; 15(3): 305–14. doi: 10.1016/S1470-2045(14)70028-2.Conroy T.,Galais M.P.,Raoul J.L.,Bouché O.,Gourgou-Bourgade S., Douillard J.Y., Etienne P.L., Boige V., Martel-Lafay I., Michel P., LlacerMoscardo C., François E. , Créhange G., Abdelghani M.B., Juzyna B., Bedenne L., Adenis A.; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol. 2014 Mar; 15(3): 305–14. doi: 10.1016/S1470-2045(14)70028-2.Markar S., Gronnier C., Duhamel A., Pasquer A., Théreaux J., du Rieu M.C., Lefevre J.H., Turner K., Luc G., Mariette C. Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option? J Clin Oncol. 2015 Nov 20; 33(33): 3866–73. doi: 10.1200/JCO.2014.59.9092.Markar S., Gronnier C., Duhamel A., Pasquer A., Théreaux J., du Rieu M.C., Lefevre J.H., Turner K., Luc G., Mariette C. Salvage Surgery After Chemoradiotherapy in the Management of Esophageal Cancer: Is It a Viable Therapeutic Option? J Clin Oncol. 2015 Nov 20; 33(33): 3866–73. doi: 10.1200/JCO.2014.59.9092.Goense L., van Rossum P.S., Ruurda J.P., van Vulpen M., Mook S., Meijer G.J., van Hillegersberg R. Radiation to the Gastric Fundus Increases the Risk of Anastomotic Leakage After Esophagectomy. Ann Thorac Surg. 2016 Dec; 102(6): 1798–1804. doi: 10.1016/j.athoracsur.2016.08.027.Goense L., van Rossum P.S., Ruurda J.P., van Vulpen M., Mook S., Meijer G.J., van Hillegersberg R. Radiation to the Gastric Fundus Increases the Risk of Anastomotic Leakage After Esophagectomy. Ann Thorac Surg. 2016 Dec; 102(6): 1798–1804. doi: 10.1016/j.athoracsur.2016.08.027.Gebski V.,Burmeister B.,Smithers B.M.,Foo K.,Zalcberg J.,Simes J.; Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007 Mar; 8(3): 226–34. doi: 10.1016/S1470-2045(07)70039-6.Gebski V.,Burmeister B.,Smithers B.M.,Foo K.,Zalcberg J.,Simes J.; Australasian Gastro-Intestinal Trials Group. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol. 2007 Mar; 8(3): 226–34. doi: 10.1016/S1470-2045(07)70039-6.Klevebro F., Johnsen G., Johnson E., Viste A., Myrnäs T., Szabo E., Jacobsen A.B., Friesland S., Tsai J.A., Persson S., Lindblad M., Lundell L., Nilsson M. Morbidity and mortality after surgery for cancer of the oesophagus and gastrooesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Eur J Surg Oncol. 2015 Jul; 41(7): 920–6. doi: 10.1016/j.ejso.2015.03.226.Klevebro F., Johnsen G., Johnson E., Viste A., Myrnäs T., Szabo E., Jacobsen A.B., Friesland S., Tsai J.A., Persson S., Lindblad M., Lundell L., Nilsson M. Morbidity and mortality after surgery for cancer of the oesophagus and gastrooesophageal junction: A randomized clinical trial of neoadjuvant chemotherapy vs. neoadjuvant chemoradiation. Eur J Surg Oncol. 2015 Jul; 41(7): 920–6. doi: 10.1016/j.ejso.2015.03.226.

The authors declare that there are no conflicts of interest present.